Relmada Therapeutics, Inc. · NASDAQ:RLMD
Relmada Therapeutics — Investor Presentation (November 2026)
31 slides from Relmada Therapeutics's investor presentation, Nov 12, 2026
Slide 1: Unlocking Life Changing Therapies Corporate Overview
Unlocking Life Changing Therapies Corporate Overview | November 2026
Slide 2: Disclosures
©2026 Relmada - All rights reserved Disclosures 2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This presentation contains statements which constitute "forward-looking statements" within the meaning of Section
Slide 3: The Promise of NDV-01: Gem/Doce Reimagined
©2026 Relmada - All rights reserved The Promise of NDV-01: Gem/Doce Reimagined TM 3 Novel, patented, sustained release, ready-to-use Gem/Doce co-formulation administered in <5 minutes Strong physician familiarity with conventional Gem/Doce Sustained release for up to 10 days extends local drug expos
Slide 4: Anticipated Milestones
©2026 Relmada - All rights reserved Anticipated Milestones 4 Candidate / Indication Phase 1 Phase 2 Phase 3 Status / Potential Next Steps NDV-011 High-Risk NMIBC (Study TRGC-011) 4Q26: Continued enrollment and long- term follow-up NDV-01 2L HR BCG-Unresponsive CIS ± Ta/T1 (SPECTRUM Cohort 2UC)2 YE26
Slide 5: NDV-01
©2026 Relmada - All rights reserved ©2026 Relmada - All rights reserved NDV-01 A novel, sustained-release, intravesical co-formulation of gemcitabine/docetaxel (Gem/Doce) being developed for patients with NMIBC NMIBC: Non-muscle invasive bladder cancer. The graphic is for artistic purposes only, not
Slide 6: Our Focus: Non-Muscle Invasive Bladder Cancer (NMIBC)
©2026 Relmada - All rights reserved Our Focus: Non-Muscle Invasive Bladder Cancer (NMIBC) 6 Flaig TW, Spiess PE, Abern M, et al. Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026;24(5):186-203. doi:10.6004/jnccn.2026.0022 75% of new cases1,2
Slide 7: Intravesical Chemotherapy is a Recommended Treatment in Intermediate and High-Risk NMIBC
©2026 Relmada - All rights reserved Intravesical Chemotherapy is a Recommended Treatment in Intermediate and High-Risk NMIBC 7 Based on NCCN Guidelines Version 3.2026, FDA product labels; * Intravesical immunotherapy includes gene therapy that causes interferon production; NMIBC: Non-muscle invasive
Slide 8: Conventional Gem/Doce is Favored by Urologists Despite Operational Challenges
©2026 Relmada - All rights reserved Most Common Intravesical Therapy in BCG-Unresponsive NMIBC Conventional Gem/Doce is Favored by Urologists Despite Operational Challenges 8 Operational Inefficiencies 1. Derived from Urology Times: Survey on Treatment Patterns and Preferences in Non–Muscle Invasive
Slide 9: NDV-01 Addresses Significant Issues with Conventional Gem/Doce
©2026 Relmada - All rights reserved vs. NDV-01 which provides sustained release of Gem/Doce for up to 10 days NDV-01 Addresses Significant Issues with Conventional Gem/Doce 9 NMIBC: Non-muscle invasive bladder cancer; Gem/Doce: Gemcitabine plus Docetaxel vs. <5 minutes in office procedure for NDV-01
Slide 10: NDV-01: Novel Sustained-Release Intravesical Gem/Doce
©2026 Relmada - All rights reserved NDV-01: Novel Sustained-Release Intravesical Gem/Doce 10 Hydrophilic Carbomer Gel Instilled into an empty bladder via standard catheter. Forms a scaffold for the NDV-01 Gem/Doce matrix. Hydrophobic NDV-01 Matrix Soft spherical matrix containing Gem/Doce forms with
Slide 11: Why It's a Durable, Attractive Market
©2026 Relmada - All rights reserved WHY IT'S A DURABLE, ATTRACTIVE MARKET Large and recurring ~63,000 new NMIBC patients/yr on top of a ~575–610K prevalent pool; high recurrence means patients cycle through multiple lines of therapies for years. The opportunity is also shifting earlier Novel agents
Slide 12: Phase 2 Study for High-Risk NMIBC
©2026 Relmada - All rights reserved 12 Phase 2 Study for High-Risk NMIBC An open-label, single-arm, single-center Phase 2 study (TRGC-011) to evaluate safety and efficacy of NDV-01 in HR NMIBC patients (NCT06663137) HR: High Risk; NMIBC: Non-muscle invasive bladder cancer
Slide 13: TRGC-011 Study Design
©2026 Relmada - All rights reserved Inclusion Criteria Primary Endpoint Secondary Endpoints Study Design 13 ONGOING TRGC-011 STUDY • High-risk NMIBC • BCG-naive, BCG-exposed, and BCG-unresponsive patients • Safety • CR Rate at anytime • CR Rate at 12 months • HG-RFS • PK (exploratory) NMIBC: Non-mus
Slide 14: Demographic Data
©2026 Relmada - All rights reserved Demographic Data 14 ONGOING TRGC-011 STUDY Efficacy-evaluable Cohort 1 patients (N=51): treated patients with ≥1 NDV-01 dose(s) post-baseline response assessment. Prior BCG doses among patients with prior BCG. BCG: Bacillus Calmette-Guérin; CIS: Carcinoma In Situ;
Slide 15: Complete Response (CR) Through Months
©2026 Relmada - All rights reserved Complete Response (CR) Through 12 Months 15 ONGOING TRGC-011 STUDY n/N % Anytime 48/51 94% 3-month 45/51 88% 6-month 38/46 83% 9-month 33/38 87% 12-month 24/31 77% • 3 of 6 patients re-induced after a 3-month non-CR achieved CR at Month 6 • 100% Progression free s
Slide 16: Extended Durability in 12-Month Complete Responders
©2026 Relmada - All rights reserved Extended Durability in 12-Month Complete Responders 16 ONGOING TRGC-011 STUDY n/N % 15-month 15/18 83% 18-month 12/14 86% • 1 patient with 12-month CR did not enter Long Term Extension (LTE) • n = 23 patients in LTE (18 evaluable at Month 15; 14 at Month 18) • 12
Slide 17: Treatment-Related AEs and Tolerability
©2026 Relmada - All rights reserved Treatment-Related AEs and Tolerability 17 ONGOING TRGC-011 STUDY 35 of 51 patients (69%) had a TRAE No ≥ Grade 3 TRAEs and no treatment-related SAEs No patients discontinued due to TRAEs • 55% transient uncomfortable urination (dysuria) • 22% hematuria • 16% urina
Slide 18: ©2026 Relmada - All rights reserved 18
©2026 Relmada - All rights reserved 18
Slide 19: SPECTRUM Phase 3 Program Built on Two Independent FDA Registrational Pathways
©2026 Relmada - All rights reserved SPECTRUM Phase 3 Program Built on Two Independent FDA Registrational Pathways 19 PHASE 3 SPECTRUM TRIAL NMIBC: non-muscle invasive bladder cancer; BCG: Bacillus Calmette-Guérin; BCG-UR: BCG-unresponsive; CIS: carcinoma in situ; HR: high risk; IR: intermediate risk
Slide 20: Cohorts 2UC/2UP: 2L BCG-Unresponsive NMIBC
©2026 Relmada - All rights reserved Inclusion Criteria Primary Endpoint Key Secondary Endpoints Cohorts 2UC/2UP: 2L BCG-Unresponsive NMIBC 20 PHASE 3 SPECTRUM TRIAL • HR BCG-UR NMIBC with CIS ± Ta/T1 • Failed one or two lines of 1L BCG-UR therapy • CR rate at anytime (2UC) • HG-RFS (2UP) • Safety •
Slide 21: Cohort IRA: Adjuvant Intermediate-Risk NMIBC
©2026 Relmada - All rights reserved Inclusion Criteria Primary Endpoint Key Secondary Endpoints Cohort IRA: Adjuvant Intermediate-Risk NMIBC 21 PHASE 3 SPECTRUM TRIAL • IR NMIBC (no high-grade) • ≥1 IBCG risk factor • TURBT within 12 weeks (± single-dose peri-operative chemotherapy) • DFS* • Safety
Slide 22: On Track to Submit NDV-01 IND by Year-End 2026
©2026 Relmada - All rights reserved On Track to Submit NDV-01 IND by Year-End 2026 and Initiate Phase 3 SPECTRUM Upon IND Clearance 22 PHASE 3 SPECTRUM TRIAL Initiate Phase 3 SPECTRUM Program Two independent registrational pathways: • 2L BCG-Unresponsive NMIBC patients • Adjuvant Intermediate-Risk N
Slide 23: NDV-01 Market Opportunity
©2026 Relmada - All rights reserved ©2026 Relmada - All rights reserved NDV-01 Market Opportunity 23
Slide 24: SPECTRUM Registrational + Potential Lifecycle Expansion Opportunity
©2026 Relmada - All rights reserved SPECTRUM Registrational + Potential Lifecycle Expansion Opportunity 24 1. Based on Internal estimates.* Includes recurrent patients. 0 50,000 100,000 150,000 Number of US Patients/yr ~12k 2L+ BCG-UR ~60k Intermediate Risk* ~80k Potential Lifecycle Expansion Opport
Slide 25: Sepranolone
©2026 Relmada - All rights reserved ©2026 Relmada - All rights reserved Sepranolone A novel GAMSA, with potential to overcome the challenges of current therapies for compulsivity disorders 25 GAMSA: a GABA-A modulating steroid antagonist. The graphic is for artistic purposes only, not a factual repr
Slide 26: Sepranolone Has the Potential to Normalize GABAA Receptor Activity
©2026 Relmada - All rights reserved Sepranolone Has the Potential to Normalize GABAA Receptor Activity 26 GABA (Υ-aminobutyric acid) is the primary neurotransmitter, involved in anxiety and compulsive disorders1,2 Allopregnanolone (ALLO) typically enhances GABAA calming effects3, 4 In some individua
Slide 27: Sepranolone: Highlights & Development Value
©2026 Relmada - All rights reserved Sepranolone: Highlights & Development Value 27 Differentiated therapeutic candidate for compulsivity-related disorders, supported by positive proof-of-concept data in Tourette's syndrome Phase 2b study in Prader-Willi syndrome (PWS) – a rare genetic disorder affec
Slide 28: On Track to Submit Sepranolone IND by Year-End 2026
©2026 Relmada - All rights reserved On Track to Submit Sepranolone IND by Year-End 2026 and Initiate Phase 2b Trial in PWS Upon IND Clearance 28 Initiation of Phase 2b study in Prader-Willi Syndrome Focus on evaluating early proof-of-concept YE26 Upon IND Clearance PWS: Prader-Willi syndrome Seprano
Slide 29: Corporate Summary
©2026 Relmada - All rights reserved ©2026 Relmada - All rights reserved Corporate Summary 29
Slide 30: Financial Overview
©2026 Relmada - All rights reserved Financial Overview 30 $202.1 million1 ~106.7 million1 1. As of September 30, 2026; ~127.9M as converted – includes ~14.9M outstanding options (weighted average exercise price of $12.58/share) and ~6.3M outstanding warrants Common shares outstanding Cash, cash equi
Slide 31: Thank You!
B Thank You!
Relmada Therapeutics — Investor Presentation (November 2026) on 6ix